Autopsy report · NCT04913220

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

“Early discontinuation based on strategic sponsor decision not driven by any safety concerns”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 7 months before it stopped.
• 46 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Sanofi

Sponsor type

Industry

Conditions

Malignant Melanoma; Squamous Cell Carcinoma of Skin

Interventions

THOR-707; Cemiplimab

Participants

46

Sites

24

Countries

Australia, Chile, France, Germany, Italy, Spain, United States

Trials that died the same way

• Goal Attainment and Physical Activity in People With Hemophilia A
  “Early discontinuation based on sponsor decision not driven by any safety concerns.” (89% match in meaning)
• The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
  “Sponsor Decision to discontinue long-term follow-up” (74% match in meaning)
• Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
  “Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.” (71% match in meaning)
• A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
  “Strategic decision by Sponsor; not due to safety reasons” (71% match in meaning)
• Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)
  “Sponsor decision to terminate study early. Decision not based on safety concerns.” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.